A case report of interstitial pneumonia induced by vedolizumab in a patient with ulcerative colitis

Medicine (Baltimore). 2024 Aug 2;103(31):e39195. doi: 10.1097/MD.0000000000039195.

Abstract

Rationale: The interstitial pneumonia (IP) linked to vedolizumab (VDZ) in patients with ulcerative colitis (UC) is rare. Prompt diagnosis and treatment can improve patient outcomes.

Patient concerns: A 39-year-old man with UC who received VDZ as sole therapy developed symptoms such as chest tightness, cough, and suffocation.

Diagnoses: IP was confirmed through pulmonary function tests, chest computed tomography, and bronchoscopic biopsy.

Interventions: The patient was given methylprednisolone and VDZ cessation.

Outcomes: The patient's symptoms improved and remained symptom-free after nearly 2 years.

Lessons: VDZ-induced IP should be considered when evaluating pulmonary infections in UC patients treated with VDZ.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Colitis, Ulcerative* / drug therapy
  • Gastrointestinal Agents* / adverse effects
  • Gastrointestinal Agents* / therapeutic use
  • Humans
  • Lung Diseases, Interstitial* / chemically induced
  • Lung Diseases, Interstitial* / drug therapy
  • Male
  • Methylprednisolone / therapeutic use

Substances

  • vedolizumab
  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • Methylprednisolone